Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CPBIO Holding CoCAIHF 58 Days Payable is 75.91 as of Jun. 2026, which is 106% above its 10-year median of 36.85. GuruFocus rates CAIHF with a GF Score™ of 58/100 and a GF Value™ of $0.16 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 928 Drug Manufacturers companies, CPBIO Holding Co ranks worse than 54.42% on this metric.
The historical rank and industry rank for CPBIO Holding Co's Days Payable or its related term are showing as below:
CAIHF'
s Days Payable Range Over the Past 10 Years
Min: 20.16 Med: 36.85 Max: 78.89
Current: 78.89
During the past 13 years, CPBIO Holding Co's highest Days Payable was 78.89. The lowest was 20.16. And the median was 36.85.
CAIHF's Days Payable is ranked worse than 54.42% of 928
companies
in the Drug Manufacturers industry
Industry Median: 88.385
vs CAIHF: 78.89
CPBIO Holding Co's Days Payable
increased
from Jun. 2025 (52.97) to Jun. 2026 (75.91).
It may suggest that CPBIO Holding Codelayed paying its suppliers.
The historical data trend for CPBIO Holding Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, CPBIO Holding Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CPBIO Holding Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, CPBIO Holding Co's Days Payable distribution charts can be found below:
* The bar in red indicates where CPBIO Holding Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CPBIO Holding Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CPBIO Holding Co (CAIHF) has a Days Payable of 75.91 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CPBIO Holding Co and its competitors. This is 106% above median its historical median of 36.85. Over the past decade, CPBIO Holding Co's Days Payable has ranged from 20.16 to 78.89. According to the industry distribution chart, CPBIO Holding Co ranks #505 out of 928 companies in the Drug Manufacturers industry, placing it in the top 54.4%.
Is CPBIO Holding Co's Days Payable too high?
CPBIO Holding Co's current Days Payable of 75.91 is 106% above median its 10-year median of 36.85. Over the past 10 years, this metric has ranged from a low of 20.16 to a high of 78.89. The Drug Manufacturers industry median Days Payable is 88.39. CPBIO Holding Co's value of 75.91 is 14.1% below this industry median. Based on the distribution chart, CPBIO Holding Co ranks #505 out of 928 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, CPBIO Holding Co has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CPBIO Holding Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, CPBIO Holding Co ranks #505 out of 928 companies for Days Payable. This places CPBIO Holding Co in the lower half of its industry. The industry median Days Payable is 88.39. CPBIO Holding Co's value of 75.91 is 14.1% below this benchmark. Historically, CPBIO Holding Co's own Days Payable has ranged from 20.16 to 78.89 over the past decade. While the company's 10-year median is 36.85 vs. the industry median of 88.39, CPBIO Holding Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.39, based on 928 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CPBIO Holding Co's current Days Payable of 75.91 is 14.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CPBIO Holding Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CPBIO Holding Co's current Days Payable is 75.91, which is 106% above median its own 10-year median of 36.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CPBIO Holding Co stock overvalued right now?
Based on GuruFocus' analysis, CPBIO Holding Co (CAIHF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.16, compared to a current price of $1.07 — trading 567.3% above its estimated fair value. The current Days Payable is 75.91, which is 106% above median its 10-year median of 36.85 and 14.1% below the Drug Manufacturers industry median of 88.39. CPBIO Holding Co's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CPBIO Holding Co (CAIHF), the current Days Payable is 75.91 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CPBIO Holding Co (CAIHF) Overvalued in 2026?
Based on GuruFocus' analysis, CPBIO Holding Co stock appears to be overvalued.
The current stock price of $1.07 is trading 567.3% above its estimated GF Value™ of $0.16.
GuruFocus considers CPBIO Holding Co to be Significantly Overvalued.
Key valuation signals for CAIHF:
Days Payable: 75.91 (106% above median its 10-year median of 36.85)
GF Value™: $0.16 vs. price of $1.07 (567.3% above fair value)
Industry Position: 14.1% below the Drug Manufacturers median (#505 of 928)
No single metric tells the full story. See the CAIHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chia Tai Enterprises International Ltd is engaged in the manufacture and sale of animal health products and chlortetracycline (CTC). The group has two reportable segments: Biotech Business and Investment Business. The Biotech Business segment is involved in the manufacture and/or sale of animal health products and chlortetracycline. The Investment Business segment is engaged in the trading of machinery and the manufacture and sale of automotive parts through the group's joint ventures and associates. It generates the majority of its revenue from the Biotech Business segment. Its geographical segments are Mainland China, which generates key revenue, Asia Pacific (excluding mainland China), the Americas, Europe, and Others.
58GF Score
Get the complete analysis for CAIHF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAIHF has been successfully added to your 
